Home  >  News
International
+ Font Resize -

Sonoma Pharma gets US FDA approval of expanded indication for Alevicyn to add antimicrobial language

Petaluma, California
Saturday, November 18, 2017, 18:00 Hrs  [IST]

Sonoma Pharmaceuticals, a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, announced that the US Food and Drug Administration (FDA) has approved an expanded claim for the company's signature dermatology product, Alevicyn Dermal Spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms.  

"This important FDA milestone further validates Alevicyn's antimicrobial activity against clinically relevant microorganisms and provides additional on-label evidence of patient benefits," said Jeff Day, president of Sonoma Pharmaceutical's dermatology division.  "These new claims differentiate Alevicyn from topical steroids and should help propel our sales growth even faster as a strong alternative to those older products."

Alevicyn products, available via prescription, provide dermatologists with a safe and clinically proven approach to management of atopic dermatitis without the side effects of topical steroids and resistance issues associated with the overuse of antibiotics. In addition, the Alevicyn products are used during and post-treatment on skin cancer surgical  procedures.  Over the last three years, there have been over 61,000 prescriptions filled for the Alevicyn family of products, valued at over $7.5 million. 

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
PITS_2017
duphat_150x60
Pre-Connect Congress 2017
acssymposium
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |